Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter M Ellis

Showing results (1-10 of 91) with videos related to

Pageof 10
Sort By:
JCO Oncology Practice|August 21, 2023
Evaluating Oncology Clinical Pathways: What Bar Are We Aiming for?Peter M Ellis
Advances in Experimental Medicine and Biology|December 16, 2015
Anti-angiogenesis in Personalized Therapy of Lung CancerPeter M Ellis
ACP Journal Club|March 6, 2007
Adjuvant vinorelbine plus cisplatin extended survival longer than observation in resected non-small-cell lung cancerPeter M Ellis
Cancers|November 12, 2013
An Evidence-Based Approach to the Use of Predictive Biomarkers in the Treatment of Non- Small Cell Lung Cancer (NSCLC)Cindy Quinton, Peter M Ellis
Journal of Thoracic Disease|January 21, 2012
Delays in the diagnosis of lung cancerPeter M Ellis, Rachel Vandermeer
Journal of Thoracic Disease|April 30, 2015
Anti-angiogenic therapy in advanced non-small cell lung carcinoma (NSCLC): is there a role in subsequent lines of therapy?Abdulaziz Al Farsi, Peter M Ellis
Journal of Personalized Medicine|January 7, 2015
Challenges in Implementing Personalized Medicine for Lung Cancer within a National Healthcare SystemDavid E Dawe, Peter M Ellis
Journal of Thoracic Disease|June 18, 2025
Perioperative toripalimab and chemotherapy in resectable non-small cell lung cancer: another weapon in the armamentariumCourtney H Coschi, Peter M Ellis
Drugs|August 26, 2016
Second-Line Treatment of Non-Small Cell Lung Cancer: New Developments for Tumours Not Harbouring Targetable Oncogenic Driver MutationsPaul C Barnfield, Peter M Ellis
Critical Reviews in Oncology/Hematology|March 13, 2012
Multitargeted anti-angiogenic agents and NSCLC: clinical update and future directionsPeter M Ellis, Khalid Al-Saleh
Pageof 10

Showing results (1-10 of 91) with videos related to

Sort By:
Pageof 10
JCO Oncology Practice|August 21, 2023
Evaluating Oncology Clinical Pathways: What Bar Are We Aiming for?Peter M Ellis
Advances in Experimental Medicine and Biology|December 16, 2015
Anti-angiogenesis in Personalized Therapy of Lung CancerPeter M Ellis
ACP Journal Club|March 6, 2007
Adjuvant vinorelbine plus cisplatin extended survival longer than observation in resected non-small-cell lung cancerPeter M Ellis
Cancers|November 12, 2013
An Evidence-Based Approach to the Use of Predictive Biomarkers in the Treatment of Non- Small Cell Lung Cancer (NSCLC)Cindy Quinton, Peter M Ellis
Journal of Thoracic Disease|January 21, 2012
Delays in the diagnosis of lung cancerPeter M Ellis, Rachel Vandermeer
Journal of Thoracic Disease|April 30, 2015
Anti-angiogenic therapy in advanced non-small cell lung carcinoma (NSCLC): is there a role in subsequent lines of therapy?Abdulaziz Al Farsi, Peter M Ellis
Journal of Personalized Medicine|January 7, 2015
Challenges in Implementing Personalized Medicine for Lung Cancer within a National Healthcare SystemDavid E Dawe, Peter M Ellis
Journal of Thoracic Disease|June 18, 2025
Perioperative toripalimab and chemotherapy in resectable non-small cell lung cancer: another weapon in the armamentariumCourtney H Coschi, Peter M Ellis
Drugs|August 26, 2016
Second-Line Treatment of Non-Small Cell Lung Cancer: New Developments for Tumours Not Harbouring Targetable Oncogenic Driver MutationsPaul C Barnfield, Peter M Ellis
Critical Reviews in Oncology/Hematology|March 13, 2012
Multitargeted anti-angiogenic agents and NSCLC: clinical update and future directionsPeter M Ellis, Khalid Al-Saleh
Pageof 10